Influence on quality of life of various treatment choices of people with drug-resistant epilepsy

Pharmacoresistant epilepsy treatment options & quality of life V1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN56117572

Enrollment

150

Registered

2020-08-26

Start date

2021-10-31

Completion date

Unknown

Last updated

2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacoresistant epilepsy in adults Nervous System Diseases Epilepsy

Interventions

Stage 1: Treatment Plan An epilepsy specialist will review an identified cohort of PWE (serial no-attenders to ED). Reviewed PWE will be divided into four groups depending on the asses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of epilepsy

Exclusion criteria

Exclusion criteria: Unable to give consent

Design outcomes

Primary

Measure	Time frame
Quality of life measured using QOLIE-31 at baseline then quarterly for 1 year	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, United Kingdom

Contacts

Public ContactSarah Lennard

sarah.lennard@nhs.net+44 (0)1209 204020

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026